{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:38:21Z","timestamp":1794368301879,"version":"4.9.0"},"reference-count":51,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>The aim of the study was to characterize effects of a multi-strain synbiotic in patients with moderate to severe irritable bowel syndrome (IBS) of all stool form types. A total of 202 adult IBS patients were randomized (1:1) and after a four-week treatment-free run-in phase and were treated either with the synbiotic or a placebo for 12 weeks. The primary endpoints were the assessment of the severity of IBS symptoms (IBS-SSS) and the improvement of IBS global symptoms (IBS-GIS). Secondary endpoints comprised adequate relief (IBS-AR scale), stool form type (Bristol Stool Form Scale), bowel movements, severity of abdominal pain and bloating, stool pressure, feeling of incomplete stool evacuation, and adverse events. A total of 201 patients completed the study. Synbiotic treatment, in comparison to placebo, significantly improved IBS-SSS and IBS-GIS scores. At the end of the treatment, 70% of patients in the synbiotic group achieved adequate relief. After 12 weeks of treatment, the secondary endpoints were favorably differentiated in the synbiotic group when compared with the placebo group. Two patients in the synbiotic group reported transient adverse events (headache). The results indicate that treatment of IBS patients with the synbiotic significantly improved all major symptoms of IBS and was well-tolerated. The ClinicalTrials.gov registration was NCT05731232.<\/jats:p>","DOI":"10.3390\/nu16101503","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T09:30:03Z","timestamp":1715851803000},"page":"1503","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effectiveness of a Balanced Nine-Strain Synbiotic in Primary-Care Irritable Bowel Syndrome Patients\u2014A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial"],"prefix":"10.3390","volume":"16","author":[{"given":"Henning","family":"Sommermeyer","sequence":"first","affiliation":[{"name":"Department of Health Sciences, Calisia University, Nowy Swiat 4, 62-800 Kalisz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4254-5466","authenticated-orcid":false,"given":"Krzysztof","family":"Chmielowiec","sequence":"additional","affiliation":[{"name":"Department of Hygiene and Epidemiology, Collegium Medicum, University of Zielona G\u00f3ra, 28 Zyty St., 65-046 Zielona G\u00f3ra, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Bernatek","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Calisia University, Nowy Swiat 4, 62-800 Kalisz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Olszewski","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Calisia University, Nowy Swiat 4, 62-800 Kalisz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Kopczynski","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Calisia University, Nowy Swiat 4, 62-800 Kalisz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2152-0876","authenticated-orcid":false,"given":"Jacek","family":"Pi\u0105tek","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Calisia University, Nowy Swiat 4, 62-800 Kalisz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(20)31548-8","article-title":"Irritable bowel syndrome","volume":"396","author":"Ford","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41575-020-0286-8","article-title":"Global burden of irritable bowel syndrome: Trends, predictions and risk factors","volume":"8","author":"Black","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jama.2020.22532","article-title":"Diagnosis and Treatment of Irritable Bowel Syndrome: A Review","volume":"325","author":"Camilleri","year":"2021","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s10620-009-0792-6","article-title":"A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity","volume":"54","author":"Drossman","year":"2009","journal-title":"Dig. Dis. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/ueg2.12153","article-title":"Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population","volume":"9","author":"Tornkvist","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cgh.2020.09.043","article-title":"Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome with Diarrhea: Cost-Benefit Analysis","volume":"20","author":"Shah","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrgastro.2014.127","article-title":"Diagnosis of IBS: Symptoms, symptom-based criteria, biomarkers or \u2018psychomarkers\u2019?","volume":"11","author":"Sood","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/ajg.2011.201","article-title":"Severity in irritable bowel syndrome: A Rome Foundation Working Team report","volume":"106","author":"Drossman","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/apt.13746","article-title":"Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome","volume":"44","author":"Blake","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S2468-1253(20)30217-X","article-title":"Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis","volume":"5","author":"Oka","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1053\/j.gastro.2016.02.028","article-title":"The Intestinal Microenvironment and Functional Gastrointestinal Disorders","volume":"150","author":"Barbara","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_15","first-page":"512","article-title":"Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome","volume":"22","author":"Tana","year":"2010","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3748\/wjg.15.2887","article-title":"Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients","volume":"15","author":"Kerckhoffs","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/j.gastro.2007.04.005","article-title":"The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects","volume":"133","author":"Kassinen","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2016.09.049","article-title":"Identification of an Intestinal Microbiota Signature Associated with Severity of Irritable Bowel Syndrome","volume":"152","author":"Tap","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.3748\/wjg.v16.i36.4532","article-title":"Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome","volume":"16","author":"Malinen","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ceccherini, C., Daniotti, S., Bearzi, C., and Re, I. (2022). Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review of Clinical Trials and Multi-Criteria Decision Analysis. Nutrients, 14.","DOI":"10.3390\/nu14132689"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3920\/BM2021.0123","article-title":"Comparing probiotic and drug interventions in irritable bowel syndrome: A meta-analysis of randomised controlled trials","volume":"13","author":"Schukking","year":"2022","journal-title":"Benef. Microbes"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.3748\/wjg.v21.i10.3072","article-title":"Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis","volume":"21","author":"Didari","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/00325481.2017.1383819","article-title":"Modulation of the gut microbiota: A focus on treatments for irritable bowel syndrome","volume":"129","author":"Harris","year":"2017","journal-title":"Postgrad. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Dale, H.F., Rasmussen, S.H., Asiller, \u00d6.\u00d6., and Lied, G.A. (2019). Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review. Nutrients, 11.","DOI":"10.3390\/nu11092048"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e16068","DOI":"10.1097\/MD.0000000000016068","article-title":"Efficacy of different probiotic protocols in irritable bowel syndrome: A network meta-analysis","volume":"98","author":"Liang","year":"2019","journal-title":"Medicine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijsu.2020.01.142","article-title":"The efficacy and safety of probiotics in patients with irritable bowel syndrome: Evidence based on 35 randomized controlled trials","volume":"75","author":"Niu","year":"2020","journal-title":"Int. J. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhang, T., Zhang, C., Zhang, J., Sun, F., and Duan, L. (2022). Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.859967"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Xie, P., Luo, M., Deng, X., Fan, J., and Xiong, L. (2023). Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Nutrients, 15.","DOI":"10.3390\/nu15173856"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/MCO.0000000000000199","article-title":"Symbiotics in irritable bowel syndrome\u2014Better than probiotics alone?","volume":"18","author":"Gracie","year":"2015","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chong, P.P., Chin, V.K., Looi, C.Y., Wong, W.F., Madhavan, P., and Yong, V.C. (2019). The Microbiome and Irritable Bowel Syndrome\u2014A Review on the Pathophysiology, Current Research and Future Therapy. Front. Microbiol., 10, Erratum in Front Microbiol. 2019, 10, 1870.","DOI":"10.3389\/fmicb.2019.01870"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Chlebicz-W\u00f3jcik, A., and \u015ali\u017cewska, K. (2021). Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review. Biomolecules, 11.","DOI":"10.3390\/biom11081154"},{"key":"ref_32","first-page":"99","article-title":"The viability and intestinal epithelial cell adhesion of probiotic strain combination\u2014In vitro study","volume":"19","author":"Olejnik","year":"2012","journal-title":"Ann. Agric. Environ. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3920\/BM2018.0080","article-title":"Persistent infection by Salmonella enterica servovar Typhimurium: Are synbiotics a therapeutic option?\u2014A case report","volume":"10","author":"Piatek","year":"2018","journal-title":"Benef. Microbes"},{"key":"ref_34","first-page":"12","article-title":"Inhibition of Carbapenem-Resistant NDM-1 Klebsiella pneumoniae isolated from a Hospital Outbreak Patient by a Synbiotic: A Non-antibiotic Treatment Option","volume":"8","author":"Piatek","year":"2019","journal-title":"Int. J. Med. Res. Health Sci."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Sommermeyer, H., Pituch, H.M., Wultanska, D., Wojtyla-Buciora, P., Piatek, J., and Bernatek, M. (2021). Inhibition of Quinolone- and Multi-Drug-Resistant Clostridioides Difficile Strains by Multi Strain Synbiotics\u2014An Option for Diarrhea Management in Nursing Facilities. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18115871"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Skrzyd\u0142o-Radoma\u0144ska, B., Prozorow-Kr\u00f3l, B., Cicho\u017c-Lach, H., Majsiak, E., Bier\u0142a, J.B., Kosikowski, W., Szczerbi\u0144ski, M., Gantzel, J., and Cukrowska, B. (2020). The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study. Nutrients, 12.","DOI":"10.3390\/nu12071999"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Skrzyd\u0142o-Radoma\u0144ska, B., Prozorow-Kr\u00f3l, B., Cicho\u017c-Lach, H., Majsiak, E., Bier\u0142a, J.B., Kanarek, E., Sowi\u0144ska, A., and Cukrowska, B. (2021). The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study. Nutrients, 13.","DOI":"10.3390\/nu13030756"},{"key":"ref_38","unstructured":"(2024, April 17). IBS Questionnaire for HCP. Available online: https:\/\/www.worldgastroenterology.org\/UserFiles\/file\/wdhd-2009-test-for-diagnosing-ibs.pdf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1023\/A:1024159226274","article-title":"Validation of irritable bowel syndrome Global Improvement Scale: An integrated symptom end point for assessing treatment efficacy","volume":"48","author":"Gordon","year":"2003","journal-title":"Dig. Dis. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/ajg.2009.13","article-title":"Adequate relief in a treatment trial with IBS patients: A prospective assessment","volume":"104","author":"Passos","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.3748\/wjg.v18.i33.4563","article-title":"Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis","volume":"18","author":"Min","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_42","first-page":"156","article-title":"The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: A randomized placebo-controlled trial","volume":"7","author":"Rogha","year":"2014","journal-title":"Gastroenterol. Hepatol. Bed. Bench"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5009\/gnl210478","article-title":"Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"17","author":"Oh","year":"2023","journal-title":"Gut Liver"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Shavakhi, A., Minakari, M., Farzamnia, S., Peykar, M.S., Taghipour, G., Tayebi, A., Hashemi, H., and Shavakhi, S. (2014). The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv. Biomed. Res., 3.","DOI":"10.4103\/2277-9175.135157"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00384-012-1552-1","article-title":"A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): Effects on symptoms, colonic transit and quality of life","volume":"28","author":"Cappello","year":"2013","journal-title":"Int. J. Colorectal. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4082\/kjfm.17.0064","article-title":"A Randomized Clinical Trial of Synbiotics in Irritable Bowel Syndrome: Dose-Dependent Effects on Gastrointestinal Symptoms and Fatigue","volume":"40","author":"Lee","year":"2019","journal-title":"Korean J. Fam. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kaptchuk, T.J., Friedlander, E., Kelley, J.M., Sanchez, M.N., Kokkotou, E., Singer, J.P., Kowalczykowski, M., Miller, F.G., Kirsch, I., and Lembo, A.J. (2010). Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015591"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.18295\/squmj.2020.20.01.003","article-title":"Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis","volume":"20","author":"Asha","year":"2020","journal-title":"Sultan Qaboos Univ. Med. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2036.1997.00168.x","article-title":"Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome","volume":"11","author":"Hahn","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1572-0241.2000.01941.x","article-title":"Further validation of the IBS-QOL: A disease-specific quality-of-life questionnaire","volume":"95","author":"Drossman","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1572-0241.2002.05616.x","article-title":"The IBS-36: A new quality of life measure for irritable bowel syndrome","volume":"97","author":"Groll","year":"2002","journal-title":"Am. J. Gastroenterol."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/10\/1503\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:43:26Z","timestamp":1760107406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/10\/1503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["nu16101503"],"URL":"https:\/\/doi.org\/10.3390\/nu16101503","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]}}}